Engineering Next-Generation Biologics to Enhance Selectivity, Durability & Clinical Impact in Complement Therapeutics

• Developing novel biologics, including bispecific antibodies, fusion proteins and engineered complement regulators, to improve therapeutic performance
• Optimizing pharmacokinetics, tissue targeting and mechanism of action to enhance efficacy while minimizing treatment burden
• Leveraging advances in protein engineering to create differentiated therapies across complement-mediated diseases

NEW SPEAKING COMPANY

Speakers:

Daniela Cipolletta

Senior Director, Immunology

Seismic Therapeutics